Is Eli Lilly Stock a Buy Right Now?
The pharmaceutical sector could be the next industry to face sweeping tariffs from the Trump administration.
One of the more interesting aspects about President Donald Trump's recent tariffs is that each major industry has shown at least some degree of weakness, regardless of whether the policies have directly affected them yet.
Take the pharmaceutical industry as an example. For the time being, Trump's tariff agenda hasn't actually done much to directly impact pharmaceutical businesses. However, the White House has certainly been dropping some breadcrumbs making executives at pharma giants wary that new tariffs could be imposed at a moment's notice. Just the idea of how the administration's tariff policies could impact these businesses has made investors jittery.
Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom. Let's explore how tariffs would impact Eli Lilly's business, and assess whether investors should buy the stock now or run for the hills instead.